- Oxford Science Enterprises (OSE) announced it closed £250 million in funding. These are the details.
Oxford Science Enterprises (OSE) – an independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford – recently announced it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to over £850 million (>$1 billion) since being launched in 2015.
These funds significantly deepen OSE’s capital pool and enable the company to identify further exceptional science from the University of Oxford, which will provide initial funding, hands-on support, and access to expert networks and start-up infrastructure, to create new spinouts across Life Sciences, Health Tech and Deep Tech. And OSE will continue to support its existing and maturing portfolio, deploying increasingly large amounts of capital in later-stage funding rounds. This ability will provide scale-up capital is crucial for OSE to enable its businesses to advance through key development milestones, maximizing their chances of success and increasing potential returns and impact.
The funding involved a diverse group of international investors with strong participation from existing and new blue-chip investors, sovereign wealth funds, family offices, pension funds, and asset managers. And since being founded in 2015, OSE has invested in over 80 ambitious companies built on Oxford science, committing £0.5 billion itself and attracting over £1 billion from blue-chip, global co-investors. To date, OSE has helped progress 27 companies from seed to Series A and 21 to Series B and beyond, including 2 IPOs and 5 trade exits.
Along with the funding, OSE provides strategic business-building and operational support to its portfolio companies, including access to a global network of entrepreneurs and advisers, and has added over 55,000 sq ft of the state-of-the-art lab and start-up space.
KEY QUOTES:
“We are delighted to successfully complete this new fundraising. Attracting such high-quality new and existing global investors reflects their enthusiasm for the strength of Oxford’s science and our plans to drive positive impact from it.”
“This fundraise comes at an exciting and pivotal time for OSE. We have built a talented team and proved our model of translating ground-breaking science into a diverse portfolio of transformational businesses. Our companies are making remarkable breakthroughs from cancer, heart failure and infectious diseases, to climate change, food security and quantum computing. Over the next few years, we expect these companies will continue to make important progress; with our ongoing efforts, and the support of our shareholders, we look forward to helping them deliver impact and returns.”
— Alexis Dormandy, Chief Executive Officer
